Division of Infectious Diseases, University of Connecticut Health Center, Farmington, CT, USA.
J Clin Transl Hepatol. 2013 Dec;1(2):109-15. doi: 10.14218/JCTH.2013.00018. Epub 2013 Dec 15.
Chronic hepatitis C virus (HCV) infection has historically been difficult to treat in the HIV-infected population, owing to generally poor responses to interferon-based therapies. The recent rapid development of directly acting antiviral agents (DAAs) against HCV has the potential to revolutionize treatment of this infection in the HIV population by improving tolerability and outcome, and, ultimately, reducing the significant burden of liver-related morbidity and mortality in this population. Clinical trials to address the safety and efficacy of novel DAAs in the HCV/HIV coinfected population are ongoing, and show much promise. The rapidity of current drug discovery in the field of HCV is both impressive and daunting for clinicians who will have to master these drugs. Going forward, the inclusion of individuals from this large and growing patient population in clinical trials will be of paramount importance.
慢性丙型肝炎病毒 (HCV) 感染在 HIV 感染者中历来难以治疗，这主要是由于干扰素为基础的治疗反应不佳。最近针对 HCV 的直接作用抗病毒药物 (DAA) 的快速发展有可能通过提高耐受性和结果，最终降低该人群中与肝脏相关的发病率和死亡率的巨大负担，从而彻底改变 HIV 人群中这种感染的治疗方法。正在进行临床试验以确定新型 DAA 在 HCV/HIV 合并感染人群中的安全性和疗效，并且显示出很大的希望。目前 HCV 领域的药物发现速度之快，让临床医生既印象深刻又望而却步，他们将不得不掌握这些药物。展望未来，将这一庞大且不断增长的患者群体纳入临床试验将至关重要。
